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Abstract
Aerococcus urinae is a Gram-positive bacterium that can cause invasive infection, including infectious endocarditis (IE), mainly in older
men. A. urinae is often misclassiﬁed in routine diagnostic laboratories. Through searches in the laboratory databases we identify 16 iso-
lates of A. urinae causing bacteraemia during a 6-year period in southern Sweden, indicating that bacteraemia with A. urinae occurs in at
least three cases per million inhabitants per year. The identity of isolates was conﬁrmed by sequencing of the 16S rRNA genes and anti-
biotic susceptibility testing identiﬁed two ciproﬂoxacin-resistant isolates. A. urinae was the only signiﬁcant pathogen isolated in all cases.
Fifteen of the 16 patients were male, 15/16 were more than 70 years old, and 12/16 had underlying urological conditions. Though a uri-
nary tract focus was suspected in the majority of cases, the bacterium was rarely found in urinary samples. Nine patients fulﬁlled the
criteria for severe sepsis and an additional four fulﬁlled the criteria for sepsis. Only one fatality was recorded. Patients were treated
mainly with beta-lactam antibiotics but ﬂuoroquinolones and clindamycin were also used. Three cases of IE were diagnosed and
these were complicated by spondylodiscitis in one case and by septic embolization to the brain in one case. An increased awareness of
A. urinae is crucial to establishing its role as an important pathogen in older men with urinary tract disease.
Keywords: Aerococcus urinae, bacteraemia, case series, infectious endocarditis, urinary tract infection
Original Submission: 21 February 2011; Revised Submission: 7 June 2011; Accepted: 10 June 2011
Editor: G. Greub
Article published online: 20 June 2011
Clin Microbiol Infect 2012; 18: 546–550
10.1111/j.1469-0691.2011.03609.x
Corresponding author: M. Rasmussen, Department of Clinical
Sciences, Division of Infection Medicine, BMC B14, Tornava¨gen 10,
221 84 Lund, Sweden
E-mail: Magnus.Rasmussen@med.lu.se
Introduction
Aerococcus urinae is a Gram-positive coccus that was identi-
ﬁed as a possible pathogen colonizing the human urinary
tract and was originally designated as an Aerococcus-like
organism [1,2]. The bacterium was recognized as a distinct
species in 1992 [3]. A. urinae shares features with staphylo-
cocci, streptococci and enterococci as the bacterium grows
in clusters, displays a-haemolysis when grown on blood agar,
and is resistant to sulphonamide [1,2]. The organism is often
misinterpreted as an a-haemolytic streptococcus in routine
laboratory practice. Though correct identiﬁcation of A. urinae
with biochemical methods is possible, sequencing of the 16S
rRNA gene remains the conﬁrmatory test for identiﬁcation
[4]. The bacterium is generally susceptible to penicillin,
vancomycin and cephalosporins, whereas it is resistant to
sulphonamides [2,5]. Some reports have claimed that the
organism is universally sensitive to ciproﬂoxacin [5], but
recent studies indicate development of resistance to this
group of antibiotics [4,6].
Aerococcus urinae is found in the urinary tract and most,
but not all, studies implicate A. urinae as a pathogen in uri-
nary tract infections [1,2,4,7,8]. Importantly, A. urinae has
been described as a cause of invasive infections such as infec-
tious endocarditis (IE) [9], spondylodiscitis [10], septicaemia
[11], cellulitis [7] and peritonitis [12]. Patients who present
with these types of severe infections are typically elderly
men with underlying urinary tract abnormalities. Of 26
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described cases of A. urinae IE, 21 patients were male and 20
were >70 years of age [11,13–18]. The case fatality in the
described cases of A. urinae IE is above 50%, suggesting that
IE with A. urinae is a very severe condition. A. urinae has the
capacity to form bioﬁlms and to aggregate human platelets,
both of which could be important virulence mechanisms in
IE [19]. The relatively low number of cases reported indi-
cates that invasive infections with A. urinae are uncommon.
Only two studies have attempted to deﬁne the incidence of
such infections. In a nationwide survey in Denmark, Chris-
tensen et al. [11] estimated the incidence of bloodstream
infections with Aerococcus-like organisms to be 0.5 cases per
1 000 000 inhabitants per year. In a Dutch report from a sin-
gle laboratory, the incidence of bloodstream infections with
A. urinae was estimated to be three cases per 1 000 000
inhabitants per year [15]. In this work we deﬁne the clinical
presentation of invasive A. urinae infections in southern
Sweden.
Methods
Isolates were from the two routine diagnostic Laboratories
of Clinical Microbiology in Lund and Malmo¨, University and
Regional Laboratories in Ska˚ne, Sweden. The laboratories
provide a service to ten hospitals, of which two are large
university hospitals, in an area with a population of approxi-
mately one million inhabitants. Both laboratories employ the
BacT/Alert blood culture system (bioMe´rieux, Marcy l’Etoile,
France) with the FA/FN aerobic and anaerobic bottles sup-
plemented with BHI solids and activated charcoal. Prelimin-
ary identiﬁcation of bacteria from a positive blood culture
relies on Gram-staining of the broth. If A. urinae is suspected
from the appearance of the Gram-stain and growth on
haematin agar, the laboratories precede with species deter-
mination with sequencing of the 16S rRNA gene (Lund) or
Vitek 2 (Malmo¨; bioMe´rieux). Growth of an a-haemolytic
bacteria in two or more blood cultures, demands a full spe-
cies identiﬁcation in both laboratories. For urine culture,
10 lL of urine was cultured on blood agar containing 5%
horse blood for 16–20 h at 37C with 5%CO2. Species
determination was carried out based on colony morphology
and antibiotic susceptibility pattern.
The laboratories store all isolates from blood cultures at
)80C for 5 years, making reclassiﬁcation of older isolates
possible. Because A. urinae is easily mistaken for an a-haemo-
lytic streptococcus, all isolates classiﬁed as ‘a-haemolytic
streptococcus’ (Lund laboratory) or ‘streptococcal species’
(Malmo¨ laboratory) between 2005 and 2010 were reviewed.
Only isolates grown from more than one blood culture
bottle were considered and all isolates classiﬁed as ‘Gram-
positive cocci in chains’ on the initial Gram stain were disre-
garded. Of the remaining isolates, those with a zone for co-
trimoxazole <12 mm were subjected to sequencing of the
16S rRNA gene. Sequence analysis of an approximately 900
base pair fragment of the 16S rRNA-gene was essentially
performed as described previously [20]. The primers
BAK11w (5¢- AGA GTT TGA TCM TGG CTC AG -3¢) and
p91E-Revers (5¢- CCC GTC AAT TCH TTT GAG T -3¢)
were used [21]. For determination of minimal inhibitory con-
centration (MIC), approximately ten colonies were sus-
pended in saline to give a density of McFarland 0.5. Plates
with Isosentitest agar (Oxoid, Basingstoke, UK) supple-
mented with 5% horse blood and NAD were inoculated with
a cotton swab, and Etest strips were applied according to
instructions from the manufacturer (AB Biodisk, Solna,
Sweden). MIC values were recorded after incubation at
37C in 5% CO2 for 24 h or, if growth was not evident after
24 h, after 48 h.
Data on clinical presentation were gathered from the
medical record of the respective patient. Organ dysfunction
caused by the infection was assessed at the time of admis-
sion according to the guidelines of the Swedish Society of
Infectious Diseases. Hypotension was deﬁned as a systolic
blood pressure <90 mmHg or a mean arterial pressure
<70 mmHg; hypoperfusion was deﬁned as a serum lactate
>3.5 mM; respiratory dysfunction was deﬁned as peripheral
oxygen saturation <86%; renal dysfunction was deﬁned as an
increase in serum creatinine levels of >45 lM; haematologi-
cal dysfunction was deﬁned as a platelet count <100 · 109/L
or PK/INR >1.5; central nervous system dysfunction was
deﬁned as confusion; and hepatic dysfunction as serum biliru-
bin >70 lM. The local research ethical committee approved
this study (2010/681).
Results and Discussion
A. urinae blood isolates
From the laboratory in Lund, ten patients with A. urinae in
blood cultures from 2008–2010 were identiﬁed. The species
identiﬁcation had been made by sequencing of the 16S rRNA
gene. In the Malmo¨ laboratory, three patients with A. urinae
in blood cultures had been recorded. The identiﬁcation had
been made by the Vitek 2 system (n = 2) and by sequencing
of the 16S rRNA gene of one isolate. One of the isolates
previously identiﬁed with the Vitek 2 system was identiﬁed
as Aerococcus sanguinicola by 16S rDNA sequencing and thus
disregarded. The other isolate identiﬁed by the Vitek 2
system had not survived freezing, making further analysis
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impossible. Using the Vitek 2 system, A. urinae can be mis-
identiﬁed as a Granulicatella [4]. One isolate of Granulicatella
from blood was identiﬁed and sequencing of the 16S rRNA
gene revealed that this isolate was A. urinae. Twenty-seven
isolates, 15 isolates from Lund and 12 isolates from the
Malmo¨ laboratory, that had been classiﬁed as streptococci
but could be A. urinae (see methods) were subjected to 16S
rDNA sequence analysis. Of these, three isolates were iden-
tiﬁed as A. urinae, whereas the remaining isolates were
mainly of different streptococcal species (data not shown).
In total, 16 isolates of A. urinae were identiﬁed. In 15
patients A. urinae was identiﬁed from more than one blood
culture. On most occasions (26 of 39 positive cultures), both
the aerobic and anaerobic bottle grew A. urinae. In ﬁve
patients A. urinae was only isolated from the anaerobic bot-
tles. For 11 patients, A. urinae was the only organism
isolated. In four patients, one bottle grew a coagulase-nega-
tive staphylococcus and in one patient the anaerobic bottle
contained an anaerobic bacterium not further characterized.
This work represents the largest case series of bactera-
emia with A. urinae. In a 6-year period we identiﬁed 16 cases
in a population of one million inhabitants, which gives an inci-
dence of approximately three cases per 1 000 000 inhabit-
ants per year, in line with a recent report from the
Netherlands [15] but signiﬁcantly higher than ﬁgures
reported from Denmark [11]. A. urinae is easily misclassiﬁed
and despite our efforts to identify and reclassify historical
isolates, we believe that several patients with A. urinae bac-
teraemia have been missed in our laboratories. A. urinae
should always be suspected when a coccus growing in clus-
ters has the appearance of a streptococcus on a plate, and
ultimate species determination should rely on sequencing of
the 16S rRNA-gene.
Lack of A. urinae in urinary cultures
For 13 patients, a urinary culture had been taken at the same
time as the blood culture. In one patient the urine grew an
aerococcus, whereas in four patients the urine grew a-hae-
molytic streptococci or Enterococcus faecalis. In ﬁve patients
the urine was sterile and in an additional three patients
other organisms were identiﬁed. We believe that A. urinae
resided in the urine of at least some of the patients. The fail-
ure to detect A. urinae could be due to a combination of mis-
identiﬁcation, suboptimal growth conditions for aerococci,
and potential aerococci being regarded as non-signiﬁcant.
Patient characteristics
Patients had a median age of 86 years (range 64–96) and 15 of
16 patients were male (Table 1). Nine patients had underlying
urinary tract diseases such as prostate hyperplasia, or cancer
TABLE 1. Patient characteristics
Age,
sex
Underlying
urological
disease
Underlying
other
disease
Initial
symptoms
SIRS
criteria
Organ
dys-function
Treatment
i.v.
Treatment
p.o. Diagnosis Remarks
91, M UC, BPH, RC Colon cancer Fe 3/4 0 PcG+Gm 0 IE Received Ci for UTI.
Spondylitis. Isolate
resistant to Ci.
96, M UC IHD Du 2/4 HT Pt, Am, PcG 0 IE Received Ci for UTI
87, M – Dementia Scrotal pain 1/3 HT Pt Cef Anal abscess Isolate resistant to Ci
81, M UC CVI Anxiety 2/4 Con Ct Am Sepsis
86, M PC, urethral
stricture
– Fe, Du 2/4 Ren Ct, PcG+Gm,
Me
0 IE Septic emboli to brain
82, M PC, Bricker
urostomy
– Fe – 0 Pt, PcG+Gm PcV+Em Sepsis Iatrogenic at nephrostomy
80, M UC – Fe 3/4 HT, HP Le, PcG 0 Sepsis Stop in UC
89, F RC – Fe, angina
pectoris
3/4 Resp Pt Cm AMI ST-elevation, TEE normal
74, M Kidney stone Dementia Fe, loin pain 2/4 0 Ct PcV+Ci Pyelitis Ureter concrement
72, M – CLL,COPD Fe, back pain 0/1 0 Cf, PcG Am Spondylitis Ru upon admission
87, M – MDS, CVI Fe, shi 2/3 HP Ip Le MDS Ru upon admission
64, M Penile cancer IHD Fe 2/3 0 Cf Ci Pyelitis
76, M BPH, bladder
cancer
Dementia Fe, shi 2/3 0 Ct 0 Sepsis At UC change
92, M – – Fe, shi, Du 1/4 0 Ct Cm Urinary
retention
78, M PC, UC – Fe 4/4 Ren, Resp Ct 0 PC Succumbed after 48 h
88, M Urethra cancer,
UC
IHD, CVI Confusion 2/2 Coa,
Con, Ren
Ct Ci+Cm Urethral
cancer
Received nephrostomy
The SIRS criteria are expressed as number of criteria met against the total number of criteria given in the medical records. Many patients received different antibiotics and
the commas indicate changes of treatment whereas a plus indicates a combined treatment.
The following abbreviations were used: Am, amoxicillin; AMI, acute myocardial infarction; BPH, benign prostate hyperplasia; Cef, cefadroxil; Cf, cefuroxime; Ci, ciproﬂoxacin;
CLL, chronic lymphocytic leukaemia; Cm, clindamycin; Coa, coagulation dysfunction; Con, confusion; COPD, chronic obstructive pulmonary disease; Ct, cefotaxime; CVI,
cerebrovascular insult with sequelae; Du, dysuria; Em, erythromycin; F, female; Fe, fever; Gm, gentamicin; HP, hypoperfusion; HT, hypotension; IE, infectious endocarditis;
IHD, ischaemic heart disease; Im, impenem; Le, levoﬂoxacin; M, male; MDS, myelodysplastic syndrome; Me, meropenem; PC, prostate cancer; PcG, penicillin G; PcV, penicillin
V; Pt, piperacillin-tazobactam; RC, renal cancer; Ren, renal dysfunction; Resp, respiratory dysfunction; Ru, residual urine; shi, shivers; TEE, transoesophageal echocardiography;
UC, urinary catheter; UTI, urinary tract infection.
548 Clinical Microbiology and Infection, Volume 18 Number 6, June 2012 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 546–550
of the penis, prostate, urinary bladder or kidney, and six
patients had a long-term urinary tract catheter. In total, 12
patients had either a diagnosed urinary tract disease or a uri-
nary tract catheter. Six patients suffered from dementia or had
sequelae after a previous stroke, three patients had ischaemic
heart disease, and two patients had haematological malignan-
cies (Table 1). Notably, none of the patients had diabetes.
Fever was a reported initial symptom in 12/16 patients
and fever (>38C) was recorded in 8/16 patients upon arrival
at the hospital. In six patients initial symptoms such as dys-
uria, haematuria or loin tenderness indicated a urinary tract
infection. Two patients had problems with their urinary tract
catheter prior to disease onset and in two patients more
than 1 L of residual urine was noted on admission. At pre-
sentation at the hospital, 12/16 patients fulﬁlled the criteria
for the systemic inﬂammatory response syndrome (SIRS)
[22] and data were partially missing for three of the remain-
ing four patients. Three patients had hypotension upon
admission, one of whom only fulﬁlled one SIRS criterion, and
an additional six fulﬁlled different criteria for organ dysfunc-
tion (Table 1). Thus in total 12 patients fulﬁlled the criteria
for sepsis and eight of these had severe sepsis. One patient
fulﬁlled the criteria for severe sepsis but not for sepsis. The
three patients that presented with hypotension responded to
ﬂuid therapy and therefore no patient was in septic shock
upon admission.
Fifteen patients survived the hospital stay and one patient
died. The non-survivor was a 78-year-old man, terminally ill
with prostate cancer, who succumbed within 48 h from
admittance. No patient received inotropic drugs or mechani-
cal ventilation. Median duration of the hospital stay for sur-
viving patients was 12 days (range 6–53 days).
In line with earlier studies, our results conﬁrm that bac-
teraemia with A. urinae is a condition that mainly affects
older males. The high frequency of underlying urinary tract
disease and the high proportion of patients with symptoms
from the urinary tract upon admission among our cases indi-
cate that A. urinae in most cases resided in the urinary tract
before dissemination to the bloodstream.
The majority of cases presented in this study fulﬁlled cri-
teria for sepsis as they had SIRS caused by infection and we
believe that the A. urinae bacteraemia was the cause of the
symptoms in all of our cases. Importantly, A. urinae was the
sole signiﬁcant pathogen isolated in all our cases. Given the
many co-morbidities and the high age of our patients we
were surprised that only one fatality occurred.
Antibiotic susceptibility and antibiotic treatment
The MICs for relevant antibiotics were determined for 14
isolates using Etests (Table 2). As expected, low MIC values
were recorded for penicillin, cefotaxime, clindamycin and
vancomycin, whereas MICs for gentamicin ranged between
0.5 and 32 mg/L. Two isolates showed resistance to cipro-
ﬂoxacin with MIC >32 mg/L.
Fourteen patients received empirical antibacterial treat-
ment with a beta-lactam antibiotic with a broad spectrum,
such as a third-generation cephalosporin, piperacillin with
tazobactam, or a carbapenem. Only two patients received a
ﬂuoroquinolone as empirical treatment; however, both these
patients were later treated with a beta-lactam antibiotic.
Intravenous treatment was given for a median time period of
7 days (range 0–40) whereas median total duration of treat-
ment was 14 days (range 2–57). Oral treatment included cip-
roﬂoxacin or levoﬂoxacin (n = 4), clindamycin (n = 3), a
beta-lactam antibiotic (n = 3), or combinations of antibiotics
(n = 3).
Aerococcus urinae is resistant to sulphamethoxazole and
resistance to ciproﬂoxacin is observed in this study and has
recently been reported [4,6]. Some patients with A. urinae
bacteraemia will receive one of these drugs as empirical
treatment for a suspected febrile UTI and development of
ﬂuoroquinolone resistance is thus troublesome.
Infectious endocarditis with A. urinae
Two of the patients were initially treated for a suspected
bacteraemic urinary tract infection with ciproﬂoxacin but
reappeared in the hospital during, or shortly after cessation
of, the antibiotic treatment with fever. In both patients
transoesophageal echocardiography (TEE) revealed vegeta-
tions on the mitralis or the aortic valves and renewed blood
cultures demonstrated continued growth of A. urinae. The
isolate from the patient with mitralis IE was resistant
(MIC > 32 mg/L) to ciproﬂoxacin. A third patient had an
aortic valve vegetation conﬁrmed by TEE. In the three
patients with IE, two had underlying urinary tract abnormali-
ties, two had permanent urinary catheters, and two
presented with symptoms suggesting urinary tract infection.
One patient with IE was treated with penicillin alone and
two patients were treated with penicillin in combination with
gentamicin. One patient suffered a cerebral insult,
presumably due to septic embolization, and one patient had
clinical signs and a scintigraphic pattern consistent with a
TABLE 2. MIC in mg/L determined for 14 A. urinae isolates
MIC50 MIC90
Penicillin G <0.016 0.032
Cefotaxime <0.016 0.125
Vancomycin 0.25 0.5
Gentamicin 2 16
Ciproﬂoxacin 0.125 32
Clindamycin 0.125 0.5
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spondylodiscitis (the patient had a pacemaker and thus MRI
could not be performed). None of the patients with IE were
subjected to valvular replacement surgery and none of the
patients died. In previous reports on A. urinae IE, the case
fatality was more than 50%, possibly indicating that more
dramatic cases tend to be published as case reports [11,13–
18]. Clinicians treating patients with A. urinae bacteraemia
should always consider the possibility of IE, though this con-
dition may not be as common as suggested by previous
reports.
Of the 13 patients not diagnosed with IE, ﬁve patients
were investigated with TEE and an additional three were
investigated with transthoracic echocardiography. From read-
ing the medical charts it appears that no evident case of IE
was missed.
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